Our Mission
The mission of Medical Device Technologies is to design, develop, manufacture and market new patented technologies in the medical device field. The company's vision is to develop enduring therapeutic solutions and products in order to reduce the complications associated with treatment of medical conditions, thereby providing improved quality of life while reducing the cost of patient care.
Our Location
Medical Device Technologies.
113 Hodil Terrace
Pittsburgh, PA 15238
Phone: 412-963-7287
Fax: 412-963-6368
Hours of operation:
Monday - Friday
8 am - 5 pm EST
Investor Information
Company Profile
Medical Device Technologies, headquartered in Pittsburgh, Pennsylvania, is a rapidly growing, privately held, development stage medical device company focusing on the development, patenting, manufacture and marketing of medical devices related to the respiratory markets. The company manufactures and sells the MVP system, a CPAP add-on family of patented medical device products with a highly defined market. The founder participated in the design of the previous Sleep Apnea Treatment devices and has improved upon the technology significantly. While perhaps being of much lesser immediate importance and market size, the other patented products covered by the technology fill niches not covered by other companies.
From its inception, the company has been funded by individual investors. The current capital required as well as capital required for the continuation of operations will be provided by selling the shares in the private placement.
Company Snapshot
- Experienced management team
- Scalable business model
- Competitive technological "break-though" designs
- Primary focus on respiratory treatment
- Strong revenue growth potential
- Patent protected products
- Clinical validation
Prevalence of Sleep Apnea
According to Marketdata Enterprises of Tampa FL., today's annual US market for CPAP devices exceeds $2.4 billion with a continued projected annual growth of 15%-18% to 2012. The US represents about 60% of the world market.
The US target market for the new sleep apnea therapy product represents 50 million individuals with a penetration of less than 10%. An estimated 12 million Americans already are diagnosed with sleep apnea. Each year an additional 300,000 to 500,000 adults develop clinically significant sleep apnea in the US. CPAP patients have a lifelong dependence on treatment.